Scarica l'app Stockscreener
3.22
2.13%
-0.07
Dopo l'orario di chiusura:
3.24
0.02
+0.62%
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com
Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia
Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan
CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK
Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Upgraded to Strong-Buy at Maxim Group - Defense World
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):